Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer

Surgery is the standard treatment for early-stage NSCLC, and platinum-based chemotherapy remains as the treatment of choice for advanced-stage NSCLC patients with na ïve EGFR status. However, overall 5-years relative survival rates are low. Interleukins (ILs) are crucial for processes associated with tumor development. In NSCLC, IL1B, IL6, IL12A, IL13 and IL16 gene polymorphisms may contribute to individual variation in terms of patient survival. The purpose of this study was to evaluate the association between IL gene polymorphisms and survival in NSCLC patients.

Source: Surgical Oncology - May 22, 2017 Category: Surgery Authors: Cristina P érez-Ramírez, Marisa Cañadas-Garre, Ahmed Alnatsha, Miguel Ángel Molina, Ana I. Robles, Eduardo Villar, Juan Ramón Delgado, María José Faus-Dáder, Miguel Ángel Calleja-Hernández Source Type: research